Regulations and compliance · Practical guide

PIC/S PI 041-1 and MHRA guidance on data integrity

An audit finding cites PIC/S and the SOP cites the MHRA. Which actual data question remains open, and which regulatory scope applies? A contract laboratory example links a specific passage in the relevant guidance to the organisation's control and its evidence.

Table of contents

At a glance

Which source helps our GMP or GDP team answer a particular data integrity question?

PIC/S PI 041-1, published in July 2021, describes good data management and integrity practices in the GMP/GDP inspection context. MHRA’s March 2018 guidance provides cross-sector GxP terminology and advice within stated limits. Both support assessment but do not replace the applicable legal basis. MHRA’s 2021 note giving precedence to an OECD document concerns GLP. It does not supersede the entire MHRA guidance.

  • Status and applicability scope to be verified prior to each individual passage.
  • Treat PIC/S as a reference guide and interpretive support, not as a standalone regulatory requirement.
  • Read the MHRA definitions together with their respective sectoral boundaries.
  • Translate source references into specific control decision criteria.

The two documents clearly identify.

PI 041-1 dated 1 July 2021 addresses data management and data integrity in regulated GMP/GDP environments. The publication covers overarching governance topics as well as questions relating to paper, electronic, and hybrid records.

The MHRA publication is titled "GxP Data Integrity Guidance and Definitions", Revision 1, March 2018. The use of this document includes the status indication available on the official publication page. A standalone saved PDF does not automatically display subsequent classification notes.

Sources: [1] [2] [3]

Distinguish application status of documents

PIC/S explains in Section 3.7 that the guideline is not intended to be a legally enforceable regulation. Therefore, a finding must be aligned with the applicable national or relevant GMP/GDP basis. This does not render the guidance obsolete; it defines its role.

Similarly, when addressing MHRA, verify the specific operation and regulated activity to which the statement refers. A useful definition may be broadly applicable across sectors, while a detailed example may be relevant only to a specific GxP area. The objective is to establish a verifiable assignment, not a ranking of "stricter" or "more lenient" approaches.

Sources: [1] [2]

Which source answers which question?

The table serves as a dedicated navigator for initiating research. It does not replace the reading of the relevant section. Document the specific reference point whenever a requirement or internal control decision is derived therefrom.

Own approach to source selection
Open questionPragmatic EntryBoundary
Term: Original record or True Copy MHRA § 6.11. Specify the exact data purpose and sectoral scope.
Paper- or hybrid controls in the GMP/GDP workflow PIC/S §§ 8 and 9.10. Own process execution and applicable basis remain decisive.
Conduct audit trail review PIC/S §§ 9.6 and 9.8. Additionally consider the requirements applicable to the relevant record review.
Data ownership and organizational requirements PIC/S §§ 5–6; MHRA §§ 3–5. No automatic requirement for identical enterprise roles.
Which source is primary for UK-GLP? GLP note on the MHRA publication page. Subsequently, review the OECD document within the appropriate scope.

Sources: [1] [2] [3]

Do not generalize the MHRA notice of 2021

The official page was updated on 27 September 2021 with a GLP note. There, the precedence of the OECD document in relation to the OECD mutual recognition system is explained. The page also outlines the complementary role of the MHRA Guidance in fostering a data integrity culture.

This does not justify a blanket replacement of the MHRA Guidance for GMP, GCP, or pharmacovigilance. Equally, it would be incorrect to infer the entire content of the OECD document solely from this statement. Any person evaluating a GLP case must specifically consider the relevant publication.

Sources: [3]

Example: A report from the contract laboratory

A manufacturer of medicinal products for human use receives a report from an order laboratory on sample L-38. The report contains the final result and the note "newly evaluated". For the process under consideration, it is specified in advance that the evaluation must be assessed with relevant parameter set, result level and reason for change. In this package, this connection is not yet recognizable.

The manufacturer should not immediately allege data manipulation solely due to the absence of an annex, nor should the final result be considered sufficient without clarification. First, it must be determined which evidence is missing, where it is available, and how it can be made accessible for the required review.

Sources: [4] [1] [2]

From Source Citation to Verifiable Decision

A reference "in accordance with PIC/S" does not address the open question raised in the example. Translate the relevant guidance into a specific expectation and then verify the actual documentation. The matrix below links these workflow steps, without evaluating any particular supplier package as either adequate or insufficient.

Own processing matrix for sample L-38
Question in the exampleTechnical starting pointSpecific next verification point
Which result value was used? Context and data processing, MHRA § 6.9. Link between report, analysis, and parameter set.
What was changed and why? Audit Trail Context, PIC/S Section 9.6. Relevant events with professional assessment.
What documentation can the client utilize? Outsourced data activities, PIC/S § 10. Actual access- and provisioning agreement and scope.
Can the decision be reconstructed later? Preservation and access, Annex 11 §§ 7.17. Proven retrieval of the required full context.

Sources: [1] [2] [5]

Accountability and realistic control effectiveness combined

A small team can consolidate multiple responsibilities within a single individual. What is essential is that functional accountability, access, and necessary controls remain clear and transparent. An organizational chart supplemented with additional roles provides little value if the involved personnel cannot access the critical data.

For L-38, the laboratory responsible party, QA, and the service provider's point of contact may jointly determine which evidence actually exists and which gaps remain. IT will be involved if export, authorization, or long-term access raises technical concerns. This involvement represents an independent implementation proposal and is not a mandatory requirement derived from the document title.

Sources: [1] [2] [5]

Prepare a reliable source attribution record

A useful note should include author, issue date, section, scope, and the resulting internal decision. Clarify the boundaries of the statement. This enables a subsequent reviewer to determine whether a requirement arises from a binding regulatory framework, an interpretation, or an internal policy.

The effort depends on how clearly the data flow and open questions are defined. Begin with the specific record rather than a lengthy collection of sources. A few relevant locations with traceable application is more helpful than numerous references lacking a clear connection.

  • Identify regulated activities and legal jurisdiction.
  • Official publication and status page to be used.
  • Read the specific passage in context.
  • Document independent control decisions and recordkeeping requirements separately.
  • Highlight sector-specific exceptions and open questions.
  • For a new edition, specifically assess the relevant statements.

Sources: [1] [3]

Project experience and collaboration

Translate a general source reference into a specific control

A reference to PIC/S or MHRA alone does not tell your team what to change. With quality and process owners, we examine a specific data gap, establish the relevant scope and original source, and identify the control already in place. Sometimes the rationale is unclear. In other cases, the control does not work as claimed. We define the evidence and actions needed so your team can explain its approach without treating guidance as additional legislation.

Frequently asked questions about PIC/S and MHRA

Is PIC/S PI 041-1 a law?

The guideline does not constitute a legally enforceable requirement. It supports the interpretation and inspection practices within the GMP/GDP context. Therefore, the applicable requirement for your operation must remain aligned with the actual basis in effect.

Sources: [1]

Has the MHRA 2018 been fully superseded?

No, not entirely. The MHRA continues to publish the March 2018 Guidance on its official website. The September 27, 2021 addendum relates to GLP: there, the OECD document takes precedence, while the MHRA Guidance remains for supplementary use. This is not a blanket replacement of the Guidance for all GxP areas.

Sources: [3]

Which source is more stringent?

A generic ranking is of limited usefulness. Compare the same specific question within the relevant regulatory domain. Different levels of detail may reflect different target audiences or applications and do not necessarily indicate a contradiction.

Sources: [1] [2]

Can a German GMP facility use MHRA terminology?

You can provide suitable professional orientation. Nevertheless, the applicable basis of the operation remains to be determined separately. In the procedure, you can identify which definition has been adopted and which own control arises from it.

Sources: [2] [6]

Does each MHRA statement apply across all GxP domains?

No. Refer to the limitations and sector-specific guidance in the document. A generally understandable definition of data is not equivalent to an identical detailed requirement for GMP, clinical studies, and pharmacovigilance.

Sources: [2]

Does a reference to ALCOA+ exist in the audit report?

He identifies an overarching principle but not yet the specific gap. Describe the affected data, missing attribute, and its significance. Subsequently, assign an appropriate source and the required evidence or correction decision.

Sources: [1] [2]

Do we need a separate SOP for each source?

A fixed document-to-SOP assignment is not justified. Procedures should govern the actual process. Multiple sources may justify the same control; an integrated approach can clearly represent these interrelationships.

Sources: [1] [5]

Must a contract laboratory always send all data without prior request?

The required review scope cannot be defined on a per-batch basis. Determine the appropriate review scope and agree on suitable availability and access rights. The final report alone may be insufficient; however, an unstructured export of all files does not constitute a structured justification.

Sources: [1] [5]

What do we do when encountering apparently contradictory sources?

First, assess the status, intended use, and full scope. Keep the remaining boundary question open, rather than selecting the more convenient statement. A specific regulatory interpretation may require additional relevant primary sources.

Sources: [1] [3]

How can source work be kept lean?

Start with a specific decision and identify the relevant reference. Document the source, your application, and the limitation. This facilitates future updates without maintaining an overwhelming general citation catalog.

Sources: [1] [2]

Sources and review date

Sources checked on 6 October 2026. PIC/S PI 041-1 dates from July 2021. The MHRA guidance dates from March 2018, with a GLP status note published in September 2021. The OECD document is referenced only through that official MHRA status note.

  1. PIC/S: PI 041-1, Data Management and Integrity1 July 2021, sections 3–7, 8.9–8.11, 9.6, 9.8–9.10, 10 and 12
  2. MHRA: GxP Data Integrity Guidance and DefinitionsRevision 1, March 2018; Sections 2–5; 6.1–6.11; Data review and archiving definitions
  3. MHRA: Guidance on GxP data integrity, Publication and GLP Notice09.03.2018; Update 27.09.2021; Details; dedicated section Good Laboratory Practice
  4. European Commission: EU GMP Chapter 4, DocumentationJanuary 2011; Principle; Records; §§ 4.1, 4.8–4.12
  5. European Commission: EU GMP Annex 11, Computerised SystemsRevision January 2011; Principle; §§ 1–4, 7, 9–13, 17
  6. European Commission: EudraLex Volume 4, current document indexRetrieved 06.10.2026; Human-GMP: Chapter 4 and Annex 11; Separate veterinary sector

Sources checked: .

Daniel Herrmann, Daniel Herrmann Consulting

Daniel Herrmann Consulting

Clarify the specific decision jointly

We support your team in linking the applicable requirement to the actual data workflow and a traceable validation evidence. Starting point are your existing documentation and the open technical question.

  • Computer system validation →

    Bring your GxP systems into validated operation, from laboratory software, MES and eQMS to ERP. We define the scope, plan risk-based tests using GAMP 5 and hand the evidence to QA for release.

Send a project enquiry Customer testimonials →